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Local anesthesia (LA) provides a
way to relieve temporary pain in a
small part of the body and has been
used for over 100 years (Fencl,
2015).
LA prevents the passage of surgical
stimuli into the central nervous
system (CNS) making a surgical
procedure less painful for the
patient (Noble, 2015).
According to Noble, “altering the
passage of stimuli from smaller
diameter neurons in a confined area
with lower drug dosages is called
LA, such as the injection of LA
around a surgical incision” (Noble,
2015, p.325).
When performing LA
administration one must be aware
of the risk of local anesthetic
systemic toxicity (LAST) (Fencl,
2015).
It is a very serious and sometimes
fatal complication to
administration. It can result from
the patient’s risk factors, current
medications or inadvertent injection
directly into the vascular systemresulting in immediate absorption
of the anesthetic agent into an
exceptionally vascular area (Fencl,
2015).
According to Stannard (2015), 20
out of 10,000 peripheral nerve
blocks (PNBs) and 4 per 10,000
epidurals result in LAST.
PNBs improve short-term pain
control, lowers pain scores from072 hours post procedure and
reduces hospital length of stay
(Joshi, Gandhi, Shah, Gadsden, &
Corman, 2016).
Early response at the first sign of
toxicity is pertinent and improves
chances of successful treatment.
Once the reaction is noticed,
immediate supportive care needs to
be initiated due to the chance of
severe cardiac depression.
Advanced Cardiac Life Support
(ACLS) should be started
immediately and is considered the
first-line treatment for this
complication (Noble, 2015).

Signs and symptoms
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o
o
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o
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o

o

The classic description is
progressive “biphasic” effect on the
CNS then to the CVS
CNS excitation progresses to
seizure or CNS depression. This is
followed by CVS excitation
(tachycardia or ventricular
arrhythmia) then depression
(bradycardia or asystole)
(Ciechanowicz & Patil, 2012).
Cardiovascular system toxicity is
classically three phases
Initial phase: hypertension and
tachycardia
Intermediate: myocardial
depression and hypotension
Terminal: peripheral vasodilation,
severe hypotension and
arrhythmias (bradycardia,
conduction blocks or asystole)
(Christie, Picard & Weinberg,
2015).
Early: metallic taste, auditory
changes, visual disturbance (mainly
focusing), lightheadedness,
apprehension, drowsiness and
numbness of tongue and lips;
Restlessness, agitation, myoclonus,
nystagmus and slurred speech
occur at high doses
The early signs are caused by
blocking inhibitory pathways in
cerebral cortex- which allows for
disinhibition of facilitator neurons
resulting in excitatory cell
dominance causing dizziness or
lightheadedness (Dewaele & Santos,
2013).
Tachycardia and hypertension can
occur after injection without
epinephrine (Weinburg, 2002).
Cardiovascular manifestations:
Dysrhythmias and conduction
delays (from prolonger PR interval
to asystole), chest pain, shortness
of breath, palpitations,
lightheadedness, diaphoresis,
hypotension, and syncope
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Systemic toxicity from local
anesthetic (LA) occurs due to
accidental intravascular injection,
absorption from the tissues or
repeated doses without balanced
elimination
The pathophysiology of LAs are
thought to be an extension of their
uses.
Blocking cardiac voltage-gated
sodium channels, prevention myocyte
depolarization, blocking
repolarization via potassium
channels and blocking sarcoplasmic
reticulum voltage-dependent calcium
channels to limit the increase of
calcium available for contraction
(Ciechanowicz & Patil, 2012).
Myocyte ATP is reduced which limits
energy available for connecting actinmyosin cycle and ion channel
involvement is extensive
(Ciechanowicz & Patil, 2012).
Bupivacaine, Levobupivacaine and
Ropivacaine are long acting amidebased LA most commonly used in
clinical practice (Ciechanowicz &
Patil, 2012).
LAs rapidly cross cell membranes
and toxicity can act in many sites
including ionotropic and
metabotropic.
In the brain, LA affects inhibitory and
excitatory pathways
In the heart, LAs can cause
conduction blocks through sodium,
potassium and calcium channelsresulting in dysrhythmias and
reduced contractility (Christie, Picard
& Weinberg, 2015).
LA can disrupt intracellular signal
originating at metabotropic
receptors- leading to reduced
monophosphate concentrations and
decreased contractility.
In addition, the heart has preference
for fats and ketone bodies. To be
oxidized, the fats must be carried
across the mitochondrial membranes
by a translocase system which is
inhibited by concentrations of LA
leading to enhanced potency
(Christie, Picard & Weinberg, 2015).
LAST can be fatal if it is not
recognized early enough!

Conclusion

Nursing Implication

Pathophysiology
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A checklist was developed by the
American Society of Regional
Anesthesia and Pain Medicine
(ASRA) for the management of LAST
(Neal et al., 2012).
Stage 1: Get help
Stage 2: Initial Focus
o
Airway management:
ventilate with 100%
oxygen
o
Seizure management:
benzodiazepines
preferred. AVOID
Propofol in patients
with cardiovascular
instability
Stage 3: Cardiac Arrhythmia
Management
o
Initiate ACLS if
needed
o
Avoid vasopressin,
calcium channel
blockers, beta
blockers or LA
o
Reduce epinephrine
does to < 1mcg/kg
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Stage 4: Lipid Emulsion Management
o
Bolus 1.5 ml/kg IV over
2 minutes
o
Continuous infusion
o
May repeat bolus
The lipid emulsion creates a lipid
phase that extracts the lipid soluble
molecules from the plasma phase
decreasing toxicity and potentially
reversing LAST (Nicholas & Thornton,
2016).
Stage 5: Stabilization
ASRA concludes:
Be prepared
Risk reduction
Detection
Treatment (Neal et al., 2012).
See Table 1
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When the effectiveness of the checklist was researched by Neal et al. (2012),
results showed improved outcomes and excellent medical management of
LAST.
Prevention measures (in a checklist form) have been put in place to help
reduce the risk of LAST by The American Society of Regional Anesthesia and
Pain Management (ASRA)
This is a helpful tool utilized by anesthesia staff to help focus on the immediate
needs of the patient and manage cardiac events for someone diagnosed with
LAST.
By educating all staff, effective management of this emergent situation will
help influence a positive patient outcome.
Comprehensive training on LAST guidelines and treatment, along with best
practice measures for patients receiving LA are essential for optimistic patient
outcomes.

Table 2. Image retrieved from http://www.nysora.com/regionalanesthesia/foundations-of-ra/3075-toxicity-of-local-anesthetics.html
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